March 10, 2026

NeoGenomics, Inc. (NEO) Stock Analysis: Exploring a 66% Potential Upside in the Healthcare Diagnostics Sector

NeoGenomics, Inc. (NASDAQ: NEO), a prominent player in the Healthcare sector’s Diagnostics & Research industry, is attracting significant investor attention with a promising potential upside of 66.06%. Based in Fort..

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a 50.96% Potential Upside

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) presents a compelling opportunity for investors, with a potential upside of 50.96% based on current analyst target projections. This biopharmaceutical company, headquartered in Rancho Cucamonga,..

GoodRx Holdings, Inc. (GDRX) Stock Analysis: Examining a 26.44% Potential Upside in the Healthcare Sector

GoodRx Holdings, Inc. (NASDAQ: GDRX), a key player in the Health Information Services industry, presents a unique investment opportunity with a compelling potential upside of 26.44%, as indicated by the..

Evolent Health, Inc. (EVH) Stock Analysis: A Compelling 70% Upside Potential in the Healthcare Sector

Evolent Health, Inc. (EVH), a notable player in the healthcare sector specializing in health information services, is capturing the attention of individual investors with its remarkable potential for upside. Trading..

Select Medical Holdings Corp (SEM) Stock Analysis: Exploring Growth Potential with a 2.31% Upside

Select Medical Holdings Corporation (NYSE: SEM) presents an intriguing opportunity for investors seeking exposure to the healthcare sector, particularly in the medical care facilities industry. With a market capitalization of..

Healthcare Services Group, Inc. (HCSG) Stock Analysis: Exploring a 16% Potential Upside

Healthcare Services Group, Inc. (NASDAQ: HCSG), a key player in the medical care facilities industry, offers investors an intriguing proposition with its unique blend of service offerings and substantial market..

Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Steady Growth in Rare Disease Focus Amidst Analyst Hold Ratings

Amicus Therapeutics, Inc. (NASDAQ: FOLD), a prominent player in the biotechnology sector, continues to gain attention with its robust pipeline aimed at treating rare diseases. Headquartered in Princeton, New Jersey,..

agilon health, inc. (AGL) Stock Analysis: Is a 57% Upside Worth the Risks?

In the ever-evolving landscape of healthcare, agilon health, inc. (NYSE: AGL) offers a unique value proposition. Based in Westerville, Ohio, agilon health specializes in providing comprehensive healthcare solutions for seniors..

Mineralys Therapeutics, Inc. (MLYS): Analyst Ratings Signal 86.77% Potential Upside for Biotech Innovator

Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a dynamic player in the biotechnology sector, is capturing investor attention with a promising potential upside of 86.77%, as per recent analyst ratings. With a..

Ligand Pharmaceuticals (LGND) Stock Analysis: Exploring a 17.48% Potential Upside

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is making waves in the biotechnology sector, capturing the attention of investors with its promising financial outlook and robust product portfolio. With a market capitalization..

Vera Therapeutics, Inc. (VERA) Stock Analysis: A Biotech Gem with Over 100% Potential Upside

Vera Therapeutics, Inc. (NASDAQ: VERA), a burgeoning player in the biotechnology sector, is capturing significant investor interest with its promising pipeline of treatments for immunological diseases. Headquartered in Brisbane, California,..

The Pennant Group, Inc. (PNTG) Stock Analysis: Impressive Revenue Growth and Analyst Consensus Point to Upside

Investors looking at The Pennant Group, Inc. (PNTG) might find themselves intrigued by its robust revenue growth and favorable analyst ratings, which suggest a potential upside. Trading on the healthcare..

Crinetics Pharmaceuticals, Inc. (CRNX): Analyst Consensus Reveals 118% Potential Upside for Rare Disease Therapeutics

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is carving a niche in the biotechnology sector with its focus on developing therapeutics for rare endocrine diseases and endocrine-related tumors. Headquartered in San Diego,..

Opko Health, Inc. (OPK) Stock Analysis: Exploring a Potential 180% Upside Amidst Challenging Financials

Opko Health, Inc. (NASDAQ: OPK) presents a fascinating case for investors intrigued by the healthcare sector’s dynamic landscape. While the company faces significant financial headwinds, compelling analyst ratings and an..

Establishment Labs Holdings Inc (ESTA) Stock Analysis: A 30% Upside in the Medical Device Sector

For investors eyeing the healthcare sector, particularly the medical devices industry, Establishment Labs Holdings Inc (NASDAQ: ESTA) represents a compelling prospect. This Austin-based company, with a market capitalization of $2.02..

Aurinia Pharmaceuticals Inc (AUPH): Investor Outlook with an 18.3% Upside Potential

Investors seeking opportunities in the healthcare sector should take a closer look at Aurinia Pharmaceuticals Inc (AUPH), a Canadian biopharmaceutical company that is making strides in the treatment of autoimmune..

BGM Group Ltd. (BGM): Investor Outlook on a Healthcare Stock with a 52-Week Range Highlighting High Volatility

BGM Group Ltd. (BGM), a Chinese company in the healthcare sector, specializes in manufacturing and distributing active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products. Despite its..

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Navigating a 147% Potential Upside in the Biotech Arena

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), a prominent player in the healthcare sector, particularly in the niche of drug manufacturing for specialty and generic medications, has captured investor attention with its..

Omnicell, Inc. (OMCL) Investor Outlook: 44% Potential Upside Beckons Savvy Investors

Omnicell, Inc. (NASDAQ: OMCL), a prominent player in the healthcare technology sector, offers a compelling opportunity for investors seeking exposure to innovative health information services. Despite current market volatility, Omnicell’s..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Exploring a Potential 218% Upside Opportunity

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company specializing in treatments for severe allergic reactions, is currently on the radar of individual investors looking for high-upside opportunities in the biotechnology..

Search

Funds

March 10, 2026

Search

Funds

March 10, 2026

FTSE 100

Funds